Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | SNCA | P37840 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7416582 | 0.83 | KDM4E (0.67) | MAPTKDM4ETNFNOD2NOD1 | |
| SCHEMBL16135452 | 0.80 | MAPT (0.51) | MAPTKDM4ETNFNOD2NOD1 | |
| SCHEMBL5144014 | 0.75 | KDM4E (0.58) | MAPTKDM4ETNFNOD2NOD1 | |
| SCHEMBL17600397 | 0.75 | MAPT (0.47) | MAPTKDM4ETNFNOD2NOD1 | |
| SCHEMBL16114904 | 0.75 | MAPT (0.47) | MAPTKDM4ETNFNOD2NOD1 | |
| SCHEMBL13362118 | 0.72 | PNMT (0.40) | KDM4ELMNASMN1; SMN2HTTSIRT2 | |
| SCHEMBL5798736 | 0.72 | MAPT (0.67) | MAPTKDM4ETNFNOD2NOD1 | |
| SCHEMBL1948890 | 0.72 | PNMT (0.42) | HTT | |
| SCHEMBL13246580 | 0.72 | MAPT (0.48) | MAPTKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL615623 | 0.69 | NOTUM (0.61) | MAPTLMNAHTTSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1142162-C | Bicyclic oxazolidinones as antibacterial agents | �������Ŷ���Լ��������˾ | 2004-03-17 | — | — | CN | disclosed |
| EP-1181288-B1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | UPJOHN CO (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20020143009-A1 | Novel bicyclic oxazolidinones as antibacterial agents | PHARMACIA & UPJOHN | 2002-10-03 | — | — | US | disclosed |
| CN-1353709-A | Bicyclic oxazolidinones as antibacterial agents | PHARMACIA & UP JOHN CO (US) | 2002-06-12 | — | — | CN | disclosed |
| US-6387896-B1 | GRAMNEGATIVE, GRAMPOSITVE BACTERIA | PHARMACIA & UPJOHN CO. | 2002-05-14 | — | — | US | disclosed |
| EP-1181288-A1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000073301-A1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143009-A1 | Novel bicyclic oxazolidinones as antibacterial agents | OXA1L, MRPL21, RPS4Y1 | MAPT 4777/4885KDM4E 3964/4885TNF 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.